Haisco Pharmaceutical Group Co., Ltd.
002653
Peringkat dalam Saham
#2012
Haisco Pharmaceutical Group Co., Ltd., along with its subsidiaries, operates... Haisco Pharmaceutical Group Co., Ltd., along with its subsidiaries, operates within China, focusing on the research, production, and distribution of a diverse range of pharmaceutical products. Their offerings span various dosage forms, including small and large volume injections, freeze-dried and conventional powder injections, and active pharmaceutical ingredients (APIs). These medications target numerous therapeutic areas such as anti-infectives, digestive system disorders, blood system conditions, nervous system ailments, parenteral nutrition, antibiotics, emergency care, anesthesiology, and oncology. Furthermore, the company provides drugs in tablet, capsule, granule, and ointment forms for cardiovascular health, infectious diseases, digestive issues, central nervous system (CNS) conditions, diabetes, and hepatic diseases. Established in 2000 and based in Shannan, China, the company adopted its current name, Haisco Pharmaceutical Group Co., Ltd., in March 2016, having previously been known as Xizang Haisco Pharmaceutical Group Co., Ltd.
Harga Saham
$9.03
Kapitalisasi Pasar
$10.30B
Perubahan (1 hari)
4.55%
Perubahan (1 tahun)
24.15%
Negara
CN
Perdagangan Haisco Pharmaceutical Group Co., Ltd. (002653)
Kategori
Healthcare
Laba untuk Haisco Pharmaceutical Group Co., Ltd. (002653)
Laba pada Jun 2026 TTM: $144.70M
Menurut laporan keuangan terbaru dari Haisco Pharmaceutical Group Co., Ltd., laba saat ini perusahaan adalah $144.70M. Pada tahun 2023, perusahaan memperoleh laba sebesar $42.74M, penurunan dibandingkan dengan laba tahun 2022 sebesar $53.15M. Laba yang ditampilkan di halaman ini adalah laba sebelum bunga dan pajak, atau disebut juga EBIT.
Riwayat laba untuk Haisco Pharmaceutical Group Co., Ltd. dari 2008 hingga 2026
Laba pada akhir setiap tahun
| Tahun | Laba | Mengubah |
|---|---|---|
| 2026 (TTM) | $144.70M | 128.15% |
| 2024 | $63.43M | 48.41% |
| 2023 | $42.74M | -19.59% |
| 2022 | $53.15M | -33.86% |
| 2021 | $80.36M | -23.86% |
| 2020 | $105.54M | 34.49% |
| 2019 | $78.47M | 67.09% |
| 2018 | $46.96M | 18.07% |
| 2017 | $39.78M | -42.90% |
| 2016 | $69.65M | 8.93% |
| 2015 | $63.94M | -21.50% |
| 2014 | $81.46M | -13.14% |
| 2013 | $93.78M | 21.75% |
| 2012 | $77.03M | 31.46% |
| 2011 | $58.59M | 6.29% |
| 2010 | $55.13M | 19.25% |
| 2009 | $46.23M | 45.27% |
| 2008 | $31.82M | 0.00% |
Laba untuk perusahaan serupa atau pesaing
| Perusahaan | Laba | Perbedaan Laba | Negara |
|---|---|---|---|
| $5.27B | 3,545.32% |
US
|
|
| $-3.09B | -2,233.33% |
US
|
|
| $-4.02B | -2,875.47% |
AU
|
|
| $1.95B | 1,248.04% |
NL
|
|
| - | - |
CH
|
